Showing
1 - 5
results of
5
for search '
Zeidan AM
'
Skip to content
Home
Collections
High Impact Articles
Jawi Collection
Malay Medicine
Forensic
Search Options
UiTM Open Access
Search by UiTM Scopus
Advanced Search
Search by Category
Discovery Service
Sources
UiTM Journals
List UiTM Journal in IR
Statistic
About
Open Access
Creative Commons Licenses
COKI | Malaysia Open Access
User Guide
Contact Us
Search Tips
FAQs
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Author
Zeidan AM
Showing
1 - 5
results of
5
for search '
Zeidan AM
'
, query time: 0.11s
Refine Results
Sort
Relevance
Date Descending
Date Ascending
Call Number
Author
Title
1
Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options
by
Lewis R
,
Bewersdorf JP
,
Zeidan
AM
Published 2021-01-01
Get full text
Article
2
Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
by
Uy N
,
Nadeau M
,
Stahl M
,
Zeidan
AM
Published 2018-04-01
Get full text
Article
3
Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
by
Bewersdorf JP
,
Jaszczur SM
,
Afifi S
,
Zhao JC
,
Zeidan
AM
Published 2019-12-01
Get full text
Article
4
Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes
by
Abou Zahr A
,
Saad Aldin E
,
Komrokji RS
,
Zeidan
AM
Published 2014-12-01
Get full text
Article
5
Cost-effectiveness of gilteritinib for relapsed/ refractory FLT3mut+ acute myeloid leukemia
by
Garnham, A.
,
Pandya, B.J
,
Qi, C.Z
,
Shah, M.V
,
Yang, H.
,
Zeidan
,
A.M
Published 2021
Call Number:
Loading...
Located:
Loading...
View Fulltext in Publisher
Article
Search Tools:
Get RSS Feed
—
Email this Search
Related Subjects
Aniline Compounds
Article
CD135 antigen
Cost-Benefit Analysis
FLT3 protein, human
Humans
Leukemia, Myeloid, Acute
Pyrazines
Quality-Adjusted Life Years
Recurrence
Survival Analysis
United States
Willingness To Pay
acute myeloid leukemia
adult
adverse event
aged
aniline derivative
azacitidine
controlled study
cost benefit analysis
cost effectiveness analysis
cytarabine
economics
etoposide
event free survival
fludarabine
fms-Like Tyrosine Kinase 3
gene mutation
genetics
Loading...